1237 ET - Jazz Pharmaceuticals' move to buy Chimerix could be the start of deal-making by the biopharma, analysts at Piper Sandler say. Piper's David Amsellem and Alex von Riesemann say the $935 million deal is a sensible and targeted use of capital that doesn't get in the way of Jazz's ability to execute on additional M&A and doesn't entail Jazz taking on development risk. Piper notes that Jazz management has previously touted capacity for a multi-billion-dollar transaction or series of deals, and the analysts say they would like to see Jazz turn its attention to bolstering its epilepsy franchise. Jazz up 2% to $141.67. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 12:37 ET (17:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。